Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, Koopman JPR, Lamers OAC, Kuijer M, Myeni SK, van Binnendijk RS, Hartog GD, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: de gruyter hlm. Clin Microbiol Infect. 2024 Mar 28:S1198-743X(24)00159-9. doi: 10.1016/j.cmi.2024.03.028. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38552793 Free article.
Deubiquitinating activity of SARS-CoV-2 papain-like protease does not influence virus replication or innate immune responses in vivo.
van Huizen M, Bloeme-Ter Horst JR, de Gruyter HLM, Geurink PP, van der Heden van Noort GJ, Knaap RCM, Nelemans T, Ogando NS, Leijs AA, Urakova N, Mark BL, Snijder EJ, Myeni SK, Kikkert M. van Huizen M, et al. Among authors: de gruyter hlm. PLoS Pathog. 2024 Mar 25;20(3):e1012100. doi: 10.1371/journal.ppat.1012100. eCollection 2024 Mar. PLoS Pathog. 2024. PMID: 38527094 Free PMC article.
Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.
Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF. Altenburg AF, et al. Among authors: de gruyter hlm. J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15. J Virol. 2016. PMID: 27581985 Free PMC article.
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH, Goeijenbier M, Moesker FM, van den Dries L, Goeijenbier S, De Gruyter HL, Lehmann MH, Mutsert Gd, van de Vijver DA, Volz A, Fouchier RA, van Gorp EC, Rimmelzwaan GF, Sutter G, Osterhaus AD. Kreijtz JH, et al. Lancet Infect Dis. 2014 Dec;14(12):1196-207. doi: 10.1016/S1473-3099(14)70963-6. Epub 2014 Oct 30. Lancet Infect Dis. 2014. PMID: 25455987 Clinical Trial.
A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model.
Kreijtz JH, Wiersma LC, De Gruyter HL, Vogelzang-van Trierum SE, van Amerongen G, Stittelaar KJ, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF. Kreijtz JH, et al. J Infect Dis. 2015 Mar 1;211(5):791-800. doi: 10.1093/infdis/jiu528. Epub 2014 Sep 22. J Infect Dis. 2015. PMID: 25246535 Free PMC article.